Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Severine Vermeire

Showing results (21-30 of 232) with videos related to

Pageof 24
Sort By:
Journal of Managed Care & Specialty Pharmacy|August 30, 2024
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature reviewPeter M Irving, Peter Hur, Raju Gautam, et al.
Journal of Crohn'S & Colitis|March 26, 2014
IBD and health-related quality of life -- discovering the true impactSanna Lönnfors, Severine Vermeire, Marco Greco, et al.
Inflammatory Bowel Diseases|January 9, 2007
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictorsTibor Hlavaty, Marc Ferrante, Liesbet Henckaerts, et al.
Expert Review of Clinical Immunology|May 13, 2014
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial targetMariangela Allocca, Gionata Fiorino, Severine Vermeire, et al.
Inflammatory Bowel Diseases|June 24, 2005
Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependentPeter Suenaert, Veerle Bulteel, Severine Vermeire, et al.
Inflammatory Bowel Diseases|December 18, 2014
Aeromonas species: an opportunistic enteropathogen in patients with inflammatory bowel diseases? A single center cohort studyTriana Lobatón, Ilse Hoffman, Severine Vermeire, et al.
Gut|January 19, 2007
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's diseaseSeverine Vermeire, Maja Noman, Gert Van Assche, et al.
Journal of Crohn'S & Colitis|February 12, 2022
Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for AllPadhmanand Sudhakar, Dahham Alsoud, Judith Wellens, et al.
BMJ Open Gastroenterology|February 6, 2023
Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBDBram Verstockt, Sare Verstockt, Jonathan Cremer, et al.
Inflammatory Bowel Diseases|March 15, 2006
Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's diseaseTibor Hlavaty, Philippe Persoons, Severine Vermeire, et al.
Pageof 24

Showing results (21-30 of 232) with videos related to

Sort By:
Pageof 24
Journal of Managed Care & Specialty Pharmacy|August 30, 2024
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature reviewPeter M Irving, Peter Hur, Raju Gautam, et al.
Journal of Crohn'S & Colitis|March 26, 2014
IBD and health-related quality of life -- discovering the true impactSanna Lönnfors, Severine Vermeire, Marco Greco, et al.
Inflammatory Bowel Diseases|January 9, 2007
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictorsTibor Hlavaty, Marc Ferrante, Liesbet Henckaerts, et al.
Expert Review of Clinical Immunology|May 13, 2014
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial targetMariangela Allocca, Gionata Fiorino, Severine Vermeire, et al.
Inflammatory Bowel Diseases|June 24, 2005
Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependentPeter Suenaert, Veerle Bulteel, Severine Vermeire, et al.
Inflammatory Bowel Diseases|December 18, 2014
Aeromonas species: an opportunistic enteropathogen in patients with inflammatory bowel diseases? A single center cohort studyTriana Lobatón, Ilse Hoffman, Severine Vermeire, et al.
Gut|January 19, 2007
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's diseaseSeverine Vermeire, Maja Noman, Gert Van Assche, et al.
Journal of Crohn'S & Colitis|February 12, 2022
Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for AllPadhmanand Sudhakar, Dahham Alsoud, Judith Wellens, et al.
BMJ Open Gastroenterology|February 6, 2023
Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBDBram Verstockt, Sare Verstockt, Jonathan Cremer, et al.
Inflammatory Bowel Diseases|March 15, 2006
Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's diseaseTibor Hlavaty, Philippe Persoons, Severine Vermeire, et al.
Pageof 24